Loading...
The founder of cryptocurrency exchange FTX and hedge fund Alameda Research, Sam Bankman-Fried, is on trial for criminal fraud and conspiracy. Bankman-Fried's defense team claims that his inadequate Adderall dosing is hindering his participation in the trial. The defense argues that Bankman-Fried requires proper medication to ensure his ability to fully engage in the proceedings. This claim raises questions about the fallen CEO's reliance on medication and its impact on his trial.
#FTX Founder's Defense Claims Inadequate Adderall Dosing Hinders Trial Participation https://t.co/1PMpn71Uik
Sam Bankman-Fried's lawyers are claiming they want to stop the FTX Trial until Thursday when Sam receives his Adderall. Judge Kaplan says Sam can get what he can find and the show must go on. Based Kaplan.
Sam Bankman-Fried, the fallen CEO of crypto exchange FTX and hedge fund Alameda Research on trial for criminal fraud and conspiracy, says he’s not getting his Adderall. Does the fallen crypto CEO actually need his meds, or is this another game? https://t.co/hI1Xt96v3I
FTX founder demands more Adderall to continue in his multi-billion dollar fraud trial https://t.co/LFf35AGDVv https://t.co/EUBBM0cfXB
Attorneys for the FTX founder have inquired about the possibility of administering extended-release ADHD medication to their client, citing his difficulties in maintaining focus throughout the trial https://t.co/3tshcChwxi
Sam Bankman-Fried is still not receiving his full prescribed dose of ADHD medication, his defense team said, which could affect the defense strategy – including the question of whether Bankman-Fried will take the stand. @realDannyNelson reports https://t.co/nuhjNxnfNY